Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Moringa oleifera
Botanical & herbal supplements

Moringa oleifera

Moringa oleifera leaf powder

Moringa oleifera is a leafy food plant sold as powders, capsules and extracts. Human metabolic findings are mixed, and convincing benefits for focus or memory have not been established. Research doses concern specific leaf preparations, not every extract. Compare the plant part, actual leaf or extract amount per serving, testing and lot-level recall status before comparing prices.

Antioxidant PathwaysInflammation PathwaysGlucose MetabolismWhole HerbFood DerivedTraditional UseClinical Research
Updated October 2026/8 min read/14 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Pregnancy8MSK's clinical herb monograph advises avoiding moringa supplements during pregnancy. Ordinary food use does not establish safety for every concentrated commercial preparation.
01

What is it?

What moringa is

7

Moringa oleifera is a tropical tree. This profile focuses on oral leaf preparations; roots, bark, seed oil and isolated constituents have different compositions. Whole-leaf powder and a concentrated extract should be compared as separate preparations.

Why the reviews disagree9
A 2026 synthesis of 20 clinical studies in metabolic conditions reported favorable pooled glucose and blood-pressure results, but described them as preliminary because study quality and results varied. Broader study inclusion can change a pooled result; this is not confirmation of a cognitive benefit.
02

Names, aliases and forms

Latin NameMoringa oleifera
Common NamesDrumstick tree; Horseradish tree; Ben nut oil tree
Plant PartLeaf powder
03

Potential effects and evidence map

Most clinical studies examine blood-sugar and cardiovascular markers, with mixed findings across small trials and reviews. A 2025 randomized-trial review rated certainty very low; 2026 reviews reported more favorable glucose or blood-pressure signals with different study selections. An exploratory food study also measured cognition in older adults, but lacked a placebo or no-food control. Convincing nootropic benefits remain unestablished.

Effect domainMagnitudeGrade
Cellular / long-term brain support13
UnknownConfidence: Low

Convincing benefits for memory or long-term brain support have not been established.

Note One exploratory food study directly measured cognition in older adults. Its lack of a placebo or no-food control and its responder analysis cannot establish a causal benefit.

0/5
C
Physical energy / endurance7
UnknownConfidence: Low

An energy or endurance benefit from moringa supplements is not established.

Note Food nutrient content does not establish a performance benefit at a supplement serving.

0/5
E
04

Typical dosages and timing

Typical
2.4-8 g/day
Not a recommendation
Lower bound
2400 mg
Profile value
Upper bound
8000 mg
Profile value
Prediabetes study12.4 g/day

Dry leaf powder in capsules was studied for 12 weeks in adults with prediabetes. The favorable glucose-marker report and the companion ancillary report describe the same participants. This is research context, not an established effective dose for healthy adults or a conversion for extracts.

Type 2 diabetes study38 g/day

Dried leaf capsules were studied for 4 weeks in adults with untreated type 2 diabetes. Glucose and HbA1c, a marker of longer-term blood sugar, did not improve significantly versus placebo. This higher research serving does not establish an effective nootropic dose.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
Study window1Cumulative
12 weeks
A study window is not an effect duration1

The featured 12-week window comes from the prediabetes leaf-powder trial. It describes how long participants were observed, not when a user should feel an effect or a recommended cycle.

No established acute timing3

The cited leaf-powder trials do not establish a reliable cognitive onset, single-dose effect duration or whole-product half-life. The overall effect horizon remains unknown; there is no evidence-based cycling schedule for a nootropic effect.

06

Safety, side effects and risk profile

Recalled lots remain a separate hazard5
FDA marked the MOGO capsule outbreak over in July 2026, but recalled bottles can remain in homes because of their long shelf life. Check the brand, lot and expiry against the linked FDA notice; recalled lots should not be consumed. An ended outbreak does not clear recalled stock.
Breastfeeding and clot-risk context14
LactMed's July 2026 review reports no serious short-term adverse effects in studied nursing mothers or their breastfed infants. Long-term infant effects and product-to-product differences remain uncertain. LactMed also advises caution in people at high risk for blood clots; this is not evidence of a common clotting effect in ordinary leaf users.
Evidence uncertainty4
Confidence: High

Limited and conflicting human findings leave efficacy and long-term use uncertain.

Note Uncertainty is separate from the healthy-adult base-risk label.

2/5
C
Interaction risk8
Confidence: Low

Drug-interaction signals are mainly preclinical; the size of any human interaction is unknown.

Note Clinical interaction magnitude is unquantified; this targeted caution does not determine the ordinary-use base rating.

1/5
D
Pregnancy / lactation caution8
Confidence: Low

Pregnancy and breastfeeding require a separate safety assessment; ordinary food use does not establish concentrated-supplement safety.

Note Pregnancy advice follows the clinical monograph. Breastfeeding evidence is discussed separately using the newer LactMed assessment; neither population determines the healthy-adult base rating.

2/5
D
Liver / kidney caution7
Confidence: Medium

A very rare hepatic reaction is possible, based on a published case.

Note An isolated case with recurrence on re-exposure is not a measured incidence or a common trial finding.

1/5
D
GI discomfort3
Confidence: Medium

One small trial reported brief diarrhea in 4 of 16 moringa recipients.

Note At the higher studied serving in type 2 diabetes, symptoms resolved within days. This targeted tolerability finding is separate from ordinary-use base risk.

1/5
C
Legal / regulatory risk12
Confidence: High

U.S. supplement sale does not mean FDA premarket approval.

Note Jurisdiction-specific regulatory context checked 2026-10-14; contamination and recalled lots are covered separately.

1/5
C
Tolerability7

Short-term leaf studies generally show good tolerability without a common serious or dose-limiting harm; this supports the minimal base rating for ordinary oral leaf use in generally healthy adults. LiverTox describes a possible very rare liver-injury association. Limited follow-up cannot establish long-term safety, and this rating does not cover every concentrated extract.

Higher studied servings can cause diarrhea3

In the small type 2 diabetes trial, 4 of 16 moringa recipients reported diarrhea that resolved within a few days. No low-blood-sugar episodes or changes in measured liver/kidney tests were reported.

Allergy and severe skin reactions8

The clinical monograph records isolated severe allergic and skin reactions. Their frequency is unknown; these case reports are not evidence that such reactions are common. A previous reaction to moringa is a reason to avoid re-exposure.

07

Interactions and cautions

Preclinical signals8

Laboratory and animal findings suggest effects on CYP3A4, an enzyme that processes some medicines, and on the diabetes medicine sitagliptin. Human clinical relevance is undetermined. Medication users need a separate interaction assessment; blood-sugar marketing is not evidence of a predictable additive drug effect.

08

Legal and regulatory status

United States12

As of 14 October 2026, FDA does not approve dietary supplements before marketing; manufacturers are responsible for compliant safety and labeling. Moringa products sold as supplements should not be assumed FDA-approved medicines. This U.S. framework does not determine the status of a particular extract in the EU, UK or another market.

09

Practical buying and quality notes

  • For a single-ingredient leaf product, total leaf grams = servings per pack × leaf grams per serving; ingredient cost per gram = pack price ÷ total leaf grams. Example: 60 servings × 0.5 g gives 30 g of leaf; a $12 pack costs $0.40 per gram before shipping. This is an arithmetic example, not a current offer or a dose recommendation. A capsule count alone is insufficient.12
  • Check whether a listing contains whole-leaf powder, an extract or a blend. Compare leaf powders by verified ingredient grams and extracts by actual extract mass and any measured marker specification. An extract ratio alone does not demonstrate clinical equivalence or greater potency. Confirm package quantity and shipping with the merchant before calculating a unit price; zero unit prices should not be read as free product.12
  • U.S. labels may declare the total weight of a proprietary blend without each ingredient's weight. If the moringa amount is undisclosed, neither a moringa dose nor a moringa-only cost per gram can be calculated from blend weight.12
  • A certificate of analysis is a report about a tested sample. Ask which batch it covers and whether microbial contamination and heavy metals were assessed. FDA does not test every supplement before sale, so a listing or generic quality badge cannot replace batch information or a recall check.12
10

FAQ

Does moringa work as a nootropic?

13

An exploratory study measured cognition after moringa-leaf food intake in older Japanese adults, but had no placebo or no-food control and used responder analyses. It cannot show that moringa caused improvement. Convincing benefits for focus or memory in healthy adults remain unestablished.

Do moringa extracts equal leaf powder?

7

No clinical conversion is established for an arbitrary extract and the leaf powders used in the cited trials. Plant part, extraction method and composition matter. A smaller extract serving or a large advertised leaf-equivalent number does not by itself show a stronger human effect.

Can moringa be compared for blood pressure or weight?

10

A 2026 review of eight randomized trials found pooled blood-pressure reductions but no significant body-weight or BMI change. Its search ended in July 2024, and preparations and populations varied. The positive blood-pressure result contrasts with the less robust 2025 synthesis, so it is not a reliable promise for an individual product.

Does organic mean a moringa product is recall-free?

11

No. FDA posted a September 2026 recall of specified Foods Alive organic moringa leaf powder pouches because of possible Salmonella contamination. Organic status alone does not establish microbial safety. Match the exact product and lot to the notice; it is not a statement that every brand is affected.

11

References

  1. Gomez-Martinez S, et al. Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. Nutrients. 2022;14(1):57.
  2. Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. Nutrients. 2022;14(9):1937.
  3. Taweerutchana R, et al. Effect of Moringa oleifera Leaf Capsules on Glycemic Control in Therapy-Naive Type 2 Diabetes Patients: A Randomized Placebo Controlled Study. Evid Based Complement Alternat Med. 2017;2017:6581390.
  4. Crisan D, et al. Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Nutrients. 2025;17(22):3501.
  5. FDA. Outbreak Investigation of Salmonella: Moringa Leaf Powder (May 2026). Updated July 17, 2026.
  6. FDA. Total Nutrition Inc. Recalls Organic Moringa Products Following Supplier-Initiated Recall Due to Possible Health Risk. June 26, 2026.
  7. NIH LiverTox. Moringa. Last update July 15, 2024.
  8. Memorial Sloan Kettering Cancer Center. Moringa oleifera.
  9. Mokgalaboni K, et al. Moringa oleifera on hyperglycemia and hypertension in metabolic diseases: Systematic review, exploratory meta-analysis and meta-regression. Metabolism Open. 2026;29:100451.
  10. Samarin MM, et al. The Effect of Moringa oleifera on Body Weight and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Food Science & Nutrition. 2026;14(5):e71899.
  11. FDA. Foods Alive Recalls Organic Moringa Leaf Powder Because of Possible Health Risk. September 4, 2026.
  12. FDA. Questions and Answers on Dietary Supplements. Accessed October 14, 2026.
  13. Hatayama K, et al. Effect of a specific food intervention with Tamogitake mushroom, Moringa leaves, or rice bran on intestinal microbiota and cognitive function in elderly Japanese. Frontiers in Nutrition. 2025;12:1585111.
  14. NIH LactMed. Moringa. Revised July 15, 2026.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.